Beam Therapeutics Inc.
BEAM
$26.75
$0.240.91%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 156.04M | 164.01M | 139.74M | 55.70M | 60.27M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 156.04M | 164.01M | 139.74M | 55.70M | 60.27M |
| Cost of Revenue | 408.66M | 415.33M | 409.62M | 411.79M | 396.28M |
| Gross Profit | -252.63M | -251.32M | -269.88M | -356.09M | -336.00M |
| SG&A Expenses | 125.40M | 120.31M | 113.82M | 110.20M | 109.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 534.06M | 535.63M | 523.44M | 521.99M | 506.25M |
| Operating Income | -378.02M | -371.62M | -383.69M | -466.29M | -445.98M |
| Income Before Tax | -85.43M | -64.89M | -78.90M | -413.55M | -397.49M |
| Income Tax Expenses | -- | -- | -- | 0.00 | 0.00 |
| Earnings from Continuing Operations | -85.43 | -64.89 | -78.90 | -413.55 | -397.49 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -85.43M | -64.89M | -78.90M | -413.55M | -397.49M |
| EBIT | -378.02M | -371.62M | -383.69M | -466.29M | -445.98M |
| EBITDA | -355.78M | -349.25M | -361.40M | -444.22M | -423.99M |
| EPS Basic | -0.81 | -0.64 | -0.96 | -4.42 | -4.50 |
| Normalized Basic EPS | -0.52 | -0.44 | -0.62 | -2.80 | -2.80 |
| EPS Diluted | -0.86 | -0.69 | -1.00 | -4.42 | -4.50 |
| Normalized Diluted EPS | -0.55 | -0.47 | -0.65 | -2.80 | -2.80 |
| Average Basic Shares Outstanding | 413.04M | 410.71M | 395.42M | 375.37M | 355.20M |
| Average Diluted Shares Outstanding | 415.09M | 412.76M | 397.47M | 375.37M | 355.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |